GlaxoSmithKline (GSK) and Pfizer recently announced that they have successfully finalized their transaction of Nimenrix and Mencevax, both of which are meningitis assets.
Nimenrix, which is a conjugate vaccine for Meningococcal serogroups A, C, W-135 and Y, and Mencevax, a polysaccharide vaccine for Meningococcal serogroups A, C, W-135 and Y, were recently purchased by Pfizer Ireland Pharmaceuticals, which is a subsidiary under Pfizer Inc. Pfizer Ireland officially owned these two vaccines as of Oct. 1, 2015.
The three-part transaction between GSK and Novartis AG requires that GSK divest these two specific vaccines. Now GSK can meet regulatory clearances to finalize its transaction with Novartis AG, which was done in March 2015. Now GSK can acquire the global vaccines business (minus influenza vaccines) from Novartis. This includes Menveo — a meningitis conjugate vaccine for Meningococcal serogroups A, C, W-135 and Y — as well as Bexsero, a Meningococcal serogroup B vaccine.
As of Oct. 1, 2015, Pfizer is now accountable for the promotions and marketing of Nimenrix and Mencevax. After Oct. 1, 2015, GSK will continue its management of all pharmacovigilance activities, product complaints and medical information inquiries, as well as distribution and managing orders.
Further details about the transaction are available online.
